Pirfenidone reduces immune-suppressive capacity of cancer-associated fibroblasts through targeting CCL17 and TNF-beta. Issue 7 (8th July 2020)

• Record Type: Journal Article
• Authors: Aboulkheyr Es, Hamidreza; Zhand, Sareh; Thiery, Jean Paul; Warkiani, Majid Ebrahimi
• Is Part Of: Integrative biology. Volume 12:Issue 7(2020)
• Page Start: 188
• Page End: 197
• Publication Date: 2020-07-08
• Subjects: cancer-associated fibroblasts -- pirfenidone -- immune-suppression -- PD-L1 -- microfluidic cancer model; Biology -- Periodicals; Technology -- Periodicals; Biological systems -- Periodicals; 570.5
• DOI: 10.1093/intbio/zyaa014
• Languages: English
• ISSNs: 1757-9694

Abstract

Abstract: Various factors in the tumor microenvironment (TME) regulate the expression of PD-L1 in carcinoma cells. The cancer-associated fibroblasts (CAFs) play a crucial role in regulating and rewiring TME to enhance their immune suppressive function and to favor the invasion of the malignant cells. Tumor progression may be retarded by targeting CAFs in the TME. Various studies highlighted the ability of targeting CAF with pirfenidone (PFD), leading to increased efficacy of chemotherapy. However, its potential for the reduction of immune-suppression capacity of CAFs remains to be elusive. Here, we assessed the effect of PFD on the expression of PD-L1 on CAF cells. Besides migration inhibitory effects of PFD on CAFs, the expression level of PD-L1 reduced in CAFs after treatment with PFD. The downstream analysis of released cytokines from CAFs showed that PFD significantly dropped the secretion of CCL17 and TNF-β, where a positive association between PFD-targeted proteins and PD-L1 was observed. These data suggest that the treatment of CAF within TME through the PFD may reduce the acquisition of CAF-mediated invasive and immune-suppressive capacity of breast carcinoma cells.